Evidence map›Paper›PMID 38722534›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution.

Javier Gavira, Jose Carlos Tapia, Alejandra Romano, Georgia Anguera, María Aguado, Aida Piedra, Freya Bosma, Sofía Sánchez, Cristina Martin, Ferran Algaba and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Javier GaviraMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain. JGavira@seom.org.ORCID http://orcid.org/0000-0001-6385-3519
Jose Carlos TapiaMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Alejandra RomanoMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0669-4440
Georgia AngueraMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6060-1110
María AguadoMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Aida PiedraMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Freya BosmaMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Sofía SánchezMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Cristina MartinMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Ferran AlgabaPathology Department, Fundació Puigvert, Cartagena 340, 08025, Barcelona, Spain.
Yolanda ArcePathology Department, Fundació Puigvert, Cartagena 340, 08025, Barcelona, Spain.
Teresa Ramón Y CajalMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.
Pablo MarotoMedical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí 89, 08025, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0030-0412

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical characteristics of patients.

methodsThis retrospective study included patients with metastatic prostate cancer who underwent molecular testing at our hospital between 2016 and 2022. We used tumor tissue, ctDNA, and lymphocytes for somatic or germline testing. We analyzed the clinical characteristics and survival outcomes.

results144 patients were tested (113 somatic, 21 germline, and 10 both). Technical issues prevented the analysis of 23 prostatic samples (18.7%). 12 (8.3%) patients had HRD. BRCA2 was the most frequent mutation (66.7%). Patients with HRD were younger (57.5 years). Patients with BRCA mutations had poorer survival (31.9 vs 56.3 months, p = 0.048).

conclusionIn our institution, 8.3% of the patients had HRD. Tumor tissue analysis failed in 18.7% of tests. ctDNA analysis is an alternative detection method. BRCA mutations are correlated with poor prognosis.

Indexed as

BRCA2 ProteinHomologous RecombinationProstatic NeoplasmsAdultAgedAged, 80 and overBRCA1 ProteinCirculating Tumor DNAGerm-Line MutationHumansMaleMiddle AgedMutationPrognosisRetrospective StudiesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCirculating Tumor DNABRCActDNAGermlineHRDProstate cancerSomatic

Identifiers

PMID38722534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.